Advanced cirrhosis of the liver, a longterm consequence of viral hepatitis or chronic alcohol abuse, is associated with generalized vasodilation of unknown origin, which contributes to potentially letjhal complications such as ascites and variceal hemorrhage. Cirrhotic patients are endotoxemic, and we have previously shown that activation of vascular cannabinoid CB1 receptors is involved in endotoxin-induced hypotension (FASEB J. 12:1035-1044, 1998). In the present reporting period we have demonstrated that rats with biliary cirrhosis, induced by ligation of the common bile duct, have low blood pressure, which can be ioncreased by the administration of the CB1 receptor antagonist SR141716A. The low blood pressure of rats with CCl4-induced cirrhosis was similarly reversed by SR141716A, which also reduced the elevated mesenteric blood flow and portal venous pressure. Monocytes from cirrhotic but not control patients or rats elicited SR141716A-sensitive hypotension when injected into normal recipient rats, and were found to contain elevated levels of the endocannabinoid anandamide. Vascular endothelial cells isolated from cirrhotic human livers removed at transplantation had a 3-fold increase in CB1 receptors as compared to endothelial cells isolated from non-cirrhotic human liver tissue. These results implicate anandamide and vascular CB1 receptors in the vasodilated state of advanced liver cirrhosis and suggest a novel approach for its pharmacological management. In another study using the radiolabeled microsphere technique, we found that cannabinoids elicit profound cerebral and coronary vasodilation in vivo by direct activation of vascular cannabinoid CB1 receptors, rather than via autoregulation, a decrease in sympathetic tone or, in the case of anandamide, via the action of a non-cannabinoid metabolite.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Intramural Research (Z01)
Project #
1Z01AA000351-01
Application #
6542040
Study Section
(LPS)
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Alcohol Abuse and Alcoholism
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Kunos, George; Osei-Hyiaman, Douglas; Bátkai, Sándor et al. (2009) Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol Sci 30:1-7
Kunos, George (2008) A tribute to Dr. Ting-Kai Li. Alcohol Clin Exp Res 32:2030
Buettner, Christoph; Muse, Evan D; Cheng, Andrew et al. (2008) Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat Med 14:667-75
Batkai, Sandor; Mukhopadhyay, Partha; Harvey-White, Judith et al. (2007) Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol Heart Circ Physiol 293:H1689-95
Mukhopadhyay, Partha; Batkai, Sandor; Rajesh, Mohanraj et al. (2007) Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol 50:528-36
Batkai, Sandor; Osei-Hyiaman, Douglas; Pan, Hao et al. (2007) Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J 21:1788-800
Milman, Garry; Maor, Yehoshua; Abu-Lafi, Saleh et al. (2006) N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci U S A 103:2428-33
Pacher, Pal; Batkai, Sandor; Kunos, George (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389-462
Begg, Malcolm; Pacher, Pal; Batkai, Sandor et al. (2005) Evidence for novel cannabinoid receptors. Pharmacol Ther 106:133-45
Wagner, Jens A; Abesser, Marco; Karcher, Jan et al. (2005) Coronary vasodilator effects of endogenous cannabinoids in vasopressin-preconstricted unpaced rat isolated hearts. J Cardiovasc Pharmacol 46:348-55

Showing the most recent 10 out of 30 publications